机械凝血症:当前的治疗方法和指导方针之间的差异
Adela Serban1, Dana Gavan2, Diana Pepine2
1Department of Cardiology, Heart Institute Niculae Stăncioiu, Cluj-Napoca, Romania; 5th Department of Internal Medicine, Iuliu Haţieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.
Trends in cardiovascular medicine
|July 27, 2023
概括
机械栓血栓症 (MVT) 的管理是复杂的,通常需要量身定制的抗血栓治疗. 本综述比较了指导方针,并提出了一种实用算法,用于优化MVT治疗策略.
科学领域:
- 心血管医学 心血管医学
- 生物材料科学 生物材料科学
背景情况:
- 血液循环系统中的异物,如机械心脏门,容易发生血栓形成.
- 适当的抗凝剂对于假体门的长期耐用性至关重要,防止机械栓血栓症 (MVT) 等并发症.
- 低于最佳的抗凝血是MVT的主要原因.
研究的目的:
- 为了比较欧洲和美国的MVT管理指南.
- 识别证据缺口和最近的研究.
- 提出 MVT 治疗的务实算法,并突出研究方向.
主要方法:
- 对现有的临床指南进行比较分析.
- 关于MVT的最新研究和临床证据的审查.
- 开发一个整合的治疗算法.
主要成果:
- MVT管理策略因临床表现 (阻塞性与非阻塞性) 和患者状况而异.
- 治疗方案包括手术,血栓溶解和优化抗凝药,选择受到手术风险和禁忌的影响.
- 的形成需要外科手术.
结论:
- MVT的管理是复杂的,根据患者的状态和机构的专业知识,治疗指示交叉.
- 现有指导方针存在微妙的差异,需要采取务实的方法.
- 需要进一步的研究来完善 MVT 管理策略.
相关概念视频
Venous Thrombosis III: Interprofessional Care
10
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
10
Mitral Stenosis III: Medical Management
13
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
13
Mitral Regurgitation III: Medical Management
18
Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
18
Mitral Valve Prolapse II: Assessment and Management
23
IntroductionA range of clinical features characterizes Mitral Valve Prolapse (MVP), but it is important to note that many individuals with MVP are asymptomatic and may remain so throughout their lives. For those who do exhibit symptoms, the following are the key clinical features:Palpitations: This is a common symptom where individuals feel an irregular or rapid heartbeat. Palpitations in MVP are often due to arrhythmias such as premature ventricular contractions or supraventricular...
23
Aortic Regurgitation III: Medical Management
25
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
25
Venous Thrombosis IV: Nursing Management
14
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
14


